title: [Role of the tumor markers CA 19-9 and carcinoembryonic antigen (CEA) in diagnosis, treatment and prognosis of pancreatic cancer].
abstract: The investigation was concerned with diagnostic sensitivity, specificity and effectiveness of assay of CA 19-9 and carcinoembryonic antigen (CEA) in the choice of treatment modality and evaluation of therapy pancreatic carcinoma (PC). Either marker has been studied in 685 examinations for PC, 68--chronic pseudotumorous pancreatitis and 24--intestinal cancer at other sites since 1995. Tumor resection for PC was carried out in 31; conservative treatment--67; chemotherapy--56 and radiotherapy--in 29 cases. In CA 19-9 examinations, diagnostic sensitivity was 90.2; specificity--72.1 and effectiveness--85.3%, while in CEA determinations, 82.5; 30.9 and 68.5%, respectively. CA 19-9 and CEA levels proved to be prognostic factors of survival. An inverse correlation was observed between median survival and tumor marker concentrations: higher basal (preoperative) level of marker in blood was matched by lower median survival. A similar relationship was identified for CEA: 5-10--14.2 months; 10.1-20 ng/ml--8.0 months; 20.1-30 ng/ml--3.9 months, and more than 30 ng/ml--4.8 months. There was a direct correlation between CA 19-9 level and tumor stage. The dynamics of tumor markers, particularly, CA 19-9 correlated with treatment effectiveness during its course.
authors.affiliation: I.P. Pavlov State Medical University, Consultative-Diagnostic Center No. 85, St. Petersburg.
authors.forename: N Iu
authors.initials: NIu
authors.lastname: Kokhanenko
authors.forename: A M
authors.initials: AM
authors.lastname: Ignashov
authors.forename: E V
authors.initials: EV
authors.lastname: Varga
authors.forename: M S
authors.initials: MS
authors.lastname: Polkanova
authors.forename: L A
authors.initials: LA
authors.lastname: Aleshina
authors.forename: A A
authors.initials: AA
authors.lastname: Kimbarovskaia
authors.forename: S K
authors.initials: SK
authors.lastname: Osipenko
authors.forename: E G
authors.initials: EG
authors.lastname: Lebedev
mesh_terms: D014408:Biomarkers, Tumor / Q000097:blood*; D018395:CA-19-9 Antigen / Q000097:blood*; D002272:Carcinoembryonic Antigen / Q000097:blood*; D003131:Combined Modality Therapy; D003937:Diagnosis, Differential; D006801:Humans; D009367:Neoplasm Staging; D010190:Pancreatic Neoplasms / Q000175:diagnosis* / Q000276:immunology / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D011237:Predictive Value of Tests; D011379:Prognosis; D012680:Sensitivity and Specificity; D016019:Survival Analysis
chemical_list: D014408:Biomarkers, Tumor; D018395:CA-19-9 Antigen; D002272:Carcinoembryonic Antigen